{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "BMY",
  "name": "Bristol-Myers Squibb Co.",
  "url": "https://orbyd.app/dossiers/BMY/",
  "json_url": "https://orbyd.app/dossiers/BMY.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Legacy-pharma re-rating: the 2026-07-30 Q2 print beat on revenue ($12.973B vs $11.745B) and reset FY26 guidance entirely above the old range ($49.0–50.0B sales, $6.75–7.00 adj EPS). The AstraZeneca merger leg was denied by Reuters on 2026-08-05 and price held anyway; what remains is a fundamental re-rate running at RSI 71.9 into a 2026-08-17 FDA action date.",
  "invalidation_trigger": "A daily close below $61 unwinds the advance built off the 2026-07-30 guidance raise; secondarily, a 2026-08-17 iberdomide action date that comes and goes without approval removes the only dated pipeline leg inside the window.",
  "catalyst_date": "2026-08-17",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "m-and-a-special-situations",
    "oncology-immunology",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Eliquis sits in the first CMS Medicare drug-price negotiation cohort, with negotiated prices effective 2026-01-01 — a permanent factor in any Eliquis revenue line.",
    "FDA target action dates are goals, not commitments; the 2026-08-17 iberdomide date can slip without a company announcement.",
    "The AstraZeneca combination was denied by Reuters on 2026-08-05. Treat recurring merger press as unconfirmed until a filing or company statement exists.",
    "Next scheduled financial catalyst after Q2 is the Q3 2026 print, expected late October 2026 — a long gap with no company-guided datapoints."
  ],
  "body_markdown": "## Current Thesis\n\nThe narrative leg on offer is a legacy-pharma re-rating: a company priced for loss-of-exclusivity decay printing a quarter that argues the trough is shallower than modelled. On 2026-07-30 Bristol-Myers reported Q2 2026 adjusted EPS of $2.04 against a $1.59 consensus and revenue of $12.973B against $11.745B, then raised FY2026 sales guidance to $49.000–50.000B from $46.000–47.500B (consensus $47.472B) and FY2026 adjusted EPS to $6.75–7.00 from $6.05–6.35 (consensus $6.34).\n\nA second leg — an AstraZeneca combination reported by Benzinga on 2026-08-02 at a $400B scale — was contradicted by a Reuters exclusive on 2026-08-05 quoting \"no discussions\" and \"never was a deal to be done.\" The stock nonetheless closed 2026-08-07 at $64.72, 1.8% under the $65.89 52-week high. What is left standing is the fundamental leg, and it is running with RSI(14) at 71.9 into a regulatory decision dated 2026-08-17.\n\n## Bull Case\n\n- **The raise is large and it is guidance, not a beat.** Both FY2026 ranges moved on 2026-07-30, with the new sales floor ($49.000B) above the prior ceiling ($47.500B) and above the $47.472B consensus. Guidance ranges that reset entirely above the old range are a different signal from a single-quarter revenue beat.\n- **Growth portfolio scale.** On the Q2 2026 call (2026-07-30) management put growth-portfolio revenue at $7.6B, +14% YoY, approaching 60% of total revenue — the mix shift the LOE-discount thesis says cannot happen fast enough.\n- **Named product momentum, Q2 2026:** Camzyos $416M (+59%), Cobenfy $63M (+81%), Qvantig $261M and described as annualising above $1B, Breyanzi +41%, Reblozyl +29%.\n- **Eliquis outlook raised to 20–25% FY2026 growth from 10–15%** (Q2 2026 call, 2026-07-30) — notable because Eliquis sat in the first CMS Medicare negotiation cohort with negotiated prices effective 2026-01-01.\n- **Sell-side revisions moved one direction after the print.** On 2026-07-31: JPMorgan Overweight PT to $73, Guggenheim Buy PT to $75, Wells Fargo Equal-Weight PT to $65, RBC Sector Perform PT to $64, Cantor Neutral PT to $59, Truist reiterated Buy. Citigroup raised to $70 on 2026-08-03; Argus upgraded to Buy with a $75 target on 2026-08-05.\n- **A dated pipeline print sits inside the window.** The FDA accepted the iberdomide NDA on 2026-02-17 with Priority Review and Breakthrough Therapy Designation, target action 2026-08-17, based on a planned MRD-negativity analysis from the Phase 3 EXCALIBER-RRMM study of iberdomide plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma.\n\n## Bear Case\n\n- **The entry is extended.** RSI(14) 71.9 at the 2026-08-07 close of $64.72, 1.8% from the 52-week high, +16.5% over three months. Buying the second week of a gap-driven advance is a different proposition from buying the print.\n- **Two of the eight post-print sell-side anchors sit at or under spot.** RBC $64 and Cantor $59 (both 2026-07-31) imply no upside from the last close; Wells Fargo $65 is fractionally above. The bull anchors cluster at $73–75.\n- **Reported revenue growth was +5.7% YoY** despite the roughly 10% beat versus consensus — the surprise measures the bar, and the bar was low.\n- **The merger leg was denied.** Reuters, 2026-08-05. Jim Cramer characterised the report as a \"fake out\" on 2026-08-03. Any premium priced on 2026-08-03 rests on no confirmed transaction, no filing and no company statement.\n- **Patent arithmetic is unresolved past FY2026.** Coverage on 2026-08-03 framed the merger speculation explicitly around patent expirations and deal economics. One raised Eliquis year does not settle 2027–2028.\n- **The 2026-08-17 decision is binary.** A complete response letter or a delay removes the only dated pipeline event inside the window.\n\n## Setup & Price Structure\n\nLast completed daily close $64.72 (2026-08-07); 52-week high $65.89; distance from high −1.8%; three-month return +16.5%; RSI(14) 71.9.\n\nTwo events are stacked in the recent tape: the 2026-07-30 earnings reaction and the 2026-08-03 merger-headline surge. The observable that carries weight is what happened after the 2026-08-05 Reuters denial — price did not round-trip through those levels, and two sessions later sat within 2% of the 52-week high. Holding a rumour-driven advance after the rumour is retracted is evidence the bid is not purely event-driven.\n\n**Life-cycle: ACCELERATING.** The dating is dense and recent — beat and raise 2026-07-30, six price-target revisions 2026-07-31, merger report 2026-08-02, surge 2026-08-03, upgrade 2026-08-05. New attention, expanding coverage, fresh headlines. The M&A sub-leg is separately DEAD as of the 2026-08-05 denial; the ACCELERATING label rests only on the earnings re-rating. It flips toward MATURING when price-target revisions stop arriving and price chops beneath the high for several weeks without a new datapoint.\n\n**Crowding and positioning observables, stated as observables:** RSI above the conventional 70 threshold; price above two of the eight targets published since 2026-07-31; no earnings inside the window, since the print already happened on 2026-07-30 and the next is roughly late October; no Form 4 activity in the recent-filings window reviewed for this note; the near-term binary is regulatory, not financial. Retail-sentiment coverage clustered on 2026-08-03 around the merger headline (\"Why Is Bristol-Myers Squibb Stock Surging Monday?\"), which is the kind of attention spike that arrives with the last buyers.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-17 — FDA target action date, iberdomide + daratumumab/dexamethasone (IberDd), relapsed/refractory multiple myeloma.** Priority Review and Breakthrough Therapy Designation; NDA accepted 2026-02-17 on EXCALIBER-RRMM MRD-negativity data. The only dated company-specific binary inside the window.\n- **~2026-09 (est.) — FDA action on the Camzyos (mavacamten) sNDA for adolescents aged 12 to <18 with symptomatic obstructive hypertrophic cardiomyopathy**, supported by SCOUT-HCM (23 on mavacamten, 21 on placebo, 28 weeks). The exact day was not published in the PDUFA calendars reviewed for this note.\n- **Beyond the window: ~2026-10-29 (est.) — Q3 2026 results.** First independent check on whether the raised $49.000–50.000B FY sales range and $6.75–7.00 adjusted EPS range hold.\n\n## Elapsed catalysts\n\n- **No fixed date — further AstraZeneca reporting.** After the 2026-08-05 Reuters denial, the burden sits on a confirmed filing or company statement; recurring press speculation without one is not a new datapoint. *(passed 4d ago)*\n\n## What Would Change Our Mind\n\nThe whole re-rating stands on one reporting date. Three things would break it.\n\nFirst, the regulatory print: if 2026-08-17 passes with a complete response letter, a delay or a narrowed label, the near-term pipeline leg disappears and the discussion reverts to Eliquis and Opdivo exclusivity arithmetic.\n\nSecond, the structure. A daily close below $61 — roughly 5.7% under the 2026-08-07 close of $64.72 — would unwind the advance built after the 2026-07-30 guidance raise and indicate the print was faded rather than accumulated. A weekly close below $58 puts price under the lowest fresh sell-side anchor on the tape (Cantor, $59, 2026-07-31) and ends the re-rating read outright.\n\nThird, the numbers themselves. FY2026 sales guidance walked back toward the prior $46.000–47.500B range at the Q3 print, or the Eliquis FY2026 growth outlook trimmed from 20–25%, would mark the raise as a first-half timing effect. Separately, if price-target revisions stop arriving and merger headlines keep recycling without a filing, the theme reads SATURATED and the marginal bid thins.\n\n## Correlation Notes\n\n- **AZN is the direct pair.** The 2026-08-02 report and the 2026-08-05 denial make AstraZeneca headlines a two-way driver here; AstraZeneca appeared in the 2026-08-03 pre-market decliners list while BMY surged, which is the standard acquirer/target split on a merger report.\n- **Sector beta.** Large-cap pharma (XLV, XPH constituents — MRK, PFE, ABBV) usually gains relative strength when risk appetite fades. On 2026-08-03 the tape did the opposite — oil down 6%, Nasdaq 100 rallying on Iran talks — and BMY still surged, so that session's move was idiosyncratic to the merger report.\n- **Policy factor common to the group.** US drug-pricing and tariff headlines move the whole cohort together. Eliquis sits in the first CMS negotiation cohort with negotiated prices effective 2026-01-01, which makes BMY a higher-sensitivity name inside that headline class.\n- **Replimune (REPL) cross-read.** RP1 secured FDA approval on 2026-08-07 after two prior rejections and a positive advisory-committee vote on 2026-07-31; the regimen was studied in combination with nivolumab in anti-PD-1-failed melanoma, so it reads as second-order support for the Opdivo franchise rather than competition against it.",
  "first_seen": "2026-08-03",
  "last_analyzed": "2026-08-08T07:21:40+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}